PIERS & BIS, sFIT:PIGF, Adrenomedullin

Status Recruiting

Clinical Trial Summary

Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.

Clinical Trial Description

Background: Pre-eclampsia, more than being proteinuric gestational hypertension alone, is a state of exaggerated systemic inflammation and remains a leading direct cause of maternal morbidity and mortality worldwide.1 Standardization of antenatal and postnatal assessment and surveillance of pre-eclampsia with protocols that recognize the systemic inflammatory model of preeclampsia have been associated with reduced maternal morbidity.2 To quantitatively asses electroencephalography (EEG) mental involvement in Pre-eclampsia is still time consuming and not always readily available. PIERS was developed and internally validate as a pre-eclampsia outcome prediction model- (Preeclampsia Integrated Estimate of RiSk) model.3 The purpose of our study was to evaluate the discriminative power of the Bispectral Index (BIS), biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio,4 and adrenomedullin mortality risk stratifier,5 to classify the degree and progression of pre-eclampsia. Methods: In 24 patients with Eclampsia or pre-eclampsia investigators will use an artefact-free 20-min mean BIS value, as well as biomarkers sFIT (soluble FMS-like Tyrosine Kinase): PIGF (Placental Growth Factor) ratio and adrenomedullin mortality risk stratifier to classify the degree of pre-eclampsia correlated the PIERS Pre-eclampsia risk assessment PIERS percentage (http://piers.cfri.ca/PIERSCalculatorH.aspx) will be calculated from patients' clinical and laboratory findings documented in their charts, compared with 24 pregnant patients without Eclampsia or pre-eclampsia. ;

Study Design

Related Conditions & MeSH terms

Eclampsia

Clinical Trial Details

NCT number	NCT02578810
Study type	Observational
Source	Suez Canal University
Contact	Ashraf Dahaba, MD
Phone	00436509006761
Email	ashraf.dahaba@medunigraz.at
Status	Recruiting
Phase
Start date	October 2016
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02911701` - Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features	Phase 4
Recruiting	`NCT06377878` - The Preeclampsia Registry
Recruiting	`NCT02020174` - The Preeclampsia Registry
Completed	`NCT05121415` - Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy
Recruiting	`NCT02920593` - A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy	Phase 4
Completed	`NCT05143710` - The Clinical and Prognostic Features of PRES
Completed	`NCT03028194` - Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia	N/A
Recruiting	`NCT05678062` - Point-of-care Ultrasound Abnormalities in Eclampsia	N/A
Unknown status	`NCT02256995` - uChek Pilot Study for Urinalysis in the Antenatal Care Setting	N/A
Completed	`NCT01751945` - Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project	N/A
Recruiting	`NCT06069102` - Optimal Blood Pressure Treatment Thresholds Postpartum	Phase 4
Recruiting	`NCT06219109` - Pulmonary Edema Resolution in Severe Preeclampsia and Eclampsia
Recruiting	`NCT06281665` - Treatment With Aspirin After Preeclampsia: TAP Trial	Phase 4
Completed	`NCT02765906` - Comparing Different Methods of Patient Education on Preeclampsia	N/A
Completed	`NCT04160923` - Incidence and Neonatal Outcome of Eclamptic Parturient in Tertiary Hospital.
Recruiting	`NCT01856387` - The Effect of neutrophil-to Lymphocyte Ratio in Preeclampsia- Eclampsia	N/A
Recruiting	`NCT03200743` - Catestatin and Hypertension in Pregnancy	N/A
Not yet recruiting	`NCT04855513` - Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial	N/A
Completed	`NCT00000534` - Calcium for Pre-Eclampsia Prevention (CPEP)	Phase 3
Recruiting	`NCT05655936` - Eliminating Severe Maternal Morbidity With Heart Health Doulas Trial	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PIERS and BIS, sFIT:PIGF, Adrenomedullin — BIS2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms